AU2021321705B2 - Novel cycloalkenone compound or salt thereof - Google Patents

Novel cycloalkenone compound or salt thereof Download PDF

Info

Publication number
AU2021321705B2
AU2021321705B2 AU2021321705A AU2021321705A AU2021321705B2 AU 2021321705 B2 AU2021321705 B2 AU 2021321705B2 AU 2021321705 A AU2021321705 A AU 2021321705A AU 2021321705 A AU2021321705 A AU 2021321705A AU 2021321705 B2 AU2021321705 B2 AU 2021321705B2
Authority
AU
Australia
Prior art keywords
compound
group
salt
methyl group
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021321705A
Other languages
English (en)
Other versions
AU2021321705A1 (en
Inventor
Atsushi Hakozaki
Takahisa NOMA
Kazuhiko Shigeno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of AU2021321705A1 publication Critical patent/AU2021321705A1/en
Application granted granted Critical
Publication of AU2021321705B2 publication Critical patent/AU2021321705B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/31—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
AU2021321705A 2020-08-07 2021-08-06 Novel cycloalkenone compound or salt thereof Active AU2021321705B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020135328 2020-08-07
JP2020-135328 2020-08-07
PCT/JP2021/029246 WO2022030606A1 (ja) 2020-08-07 2021-08-06 新規なシクロアルケノン化合物又はその塩

Publications (2)

Publication Number Publication Date
AU2021321705A1 AU2021321705A1 (en) 2023-03-09
AU2021321705B2 true AU2021321705B2 (en) 2024-02-29

Family

ID=80118163

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021321705A Active AU2021321705B2 (en) 2020-08-07 2021-08-06 Novel cycloalkenone compound or salt thereof

Country Status (11)

Country Link
US (1) US20230295068A1 (https=)
EP (1) EP4194435A4 (https=)
JP (1) JP7109705B2 (https=)
KR (1) KR20230043923A (https=)
CN (1) CN116096361B (https=)
AU (1) AU2021321705B2 (https=)
BR (1) BR112023001832A2 (https=)
CA (1) CA3188292A1 (https=)
MX (1) MX2023001536A (https=)
TW (1) TWI829001B (https=)
WO (1) WO2022030606A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4477642A4 (en) * 2022-02-09 2026-02-25 Taiho Pharmaceutical Co Ltd CRYSTALLINE FORM OF CYCLOHEXENONE COMPOUND

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001515058A (ja) * 1997-08-13 2001-09-18 明治乳業株式会社 シクロヘキセノン長鎖アルコール及びこれを含有する医薬
JP2002241271A (ja) * 2001-02-19 2002-08-28 Meiji Milk Prod Co Ltd 排尿障害治療剤
JP2019504018A (ja) * 2015-12-17 2019-02-14 バイオエレクトロン テクノロジー コーポレイション 酸化ストレス障害を処置するためのフルオロアルキル、フルオロアルコキシ、フェノキシ、ヘテロアリールオキシ、アルコキシ、およびアミノ１，４−ベンゾキノン誘導体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
ES2849425T3 (es) 2016-01-22 2021-08-18 Taiho Pharmaceutical Co Ltd Método de fabricación de alcohol de cadena larga de ciclohexenona de alta pureza
TWI831738B (zh) * 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001515058A (ja) * 1997-08-13 2001-09-18 明治乳業株式会社 シクロヘキセノン長鎖アルコール及びこれを含有する医薬
JP2002241271A (ja) * 2001-02-19 2002-08-28 Meiji Milk Prod Co Ltd 排尿障害治療剤
JP2019504018A (ja) * 2015-12-17 2019-02-14 バイオエレクトロン テクノロジー コーポレイション 酸化ストレス障害を処置するためのフルオロアルキル、フルオロアルコキシ、フェノキシ、ヘテロアリールオキシ、アルコキシ、およびアミノ１，４−ベンゾキノン誘導体

Also Published As

Publication number Publication date
CA3188292A1 (en) 2022-02-10
TW202216650A (zh) 2022-05-01
US20230295068A1 (en) 2023-09-21
JP7109705B2 (ja) 2022-07-29
TWI829001B (zh) 2024-01-11
MX2023001536A (es) 2023-03-08
BR112023001832A2 (pt) 2023-02-23
WO2022030606A1 (ja) 2022-02-10
KR20230043923A (ko) 2023-03-31
JPWO2022030606A1 (https=) 2022-02-10
CN116096361A (zh) 2023-05-09
EP4194435A1 (en) 2023-06-14
AU2021321705A1 (en) 2023-03-09
EP4194435A4 (en) 2024-09-25
CN116096361B (zh) 2025-10-10

Similar Documents

Publication Publication Date Title
EP3893889B1 (en) Thrb receptor agonist compound and preparation method and use thereof
EP3650449B1 (en) Fxr receptor agonist
US9447140B2 (en) Cholest-4-en-3-one oxime derivatives, pharmaceutical compositions containing same, and preparation method
US11208418B2 (en) Nitrogenous tricyclic compounds and uses thereof in medicine
US11352367B2 (en) Indene derivatives useful in treating pain and inflammation
JP2010517958A (ja) ＰＤＥ５インヒビターとして有用な６−ベンジル−２，３，４，７−テトラヒドロ−インドロ［２，３−ｃ］キノリン化合物
US10105373B2 (en) Fused triterpene compounds and uses thereof
CN116354935A (zh) 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途
AU2021321705B2 (en) Novel cycloalkenone compound or salt thereof
EP3413892B1 (en) Tetrahydroisoquinoline derivatives
US20240336562A1 (en) Compound serving as nlrp3 inhibitor
US12274694B2 (en) Dizocilpine derivatives as peripheral NMDA receptor antagonists
US8530504B2 (en) Pyrazolothiazole compound
WO2021244542A1 (zh) 3,4-二氢异喹啉类化合物及其应用
CN112243437A (zh) 含丙烯酰基的核转运调节剂及其用途
US20230002366A1 (en) Indene derivatives useful in treating pain and inflammation
EP2546255A1 (en) Benzazepine compound
CN121001992A (zh) 咪唑基与二硝基苯基结合的衍生物及其用途
HK40087434A (zh) 新型环烯酮化合物或其盐
HK40087434B (zh) 新型环烯酮化合物或其盐
CN116209655A (zh) 突变型idh1和idh2抑制剂及其应用
WO2025067414A1 (zh) 吡唑羧酸衍生物及其在医药上的应用
HK40077141A (en) Tetrahydroisoquinoline derivative
WO2022022678A1 (zh) 一种吡嗪类化合物及其制备方法和应用
JP2020516583A (ja) 肝臓送達に基づく抗ｃ型肝炎プロドラッグであるヌクレオシド環状リン酸エステル化合物及びその使用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)